---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-083352"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:55:07.100532+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# Biomea Fusion reports initial data from first two T1D patients dosed with BMF-219; C-peptide increased

## Summary
- Patient 1 (200 mg): fasting C-peptide +57% at week 4, +80% at week 8; MMTT C-peptide index AUC +12% and +40%.
- Patient 2 (100 mg): fasting C-peptide +16% at week 4; MMTT C-peptide index AUC +30%; reduced daily insulin usage.
- BMF-219 well tolerated in both patients; no safety signals reported.
- Open-label portion of COVALENT-112 (n=40) with 12-week dosing data expected in 2024.
- First type 2 diabetes patient in COVALENT-111 discontinued metformin after week 40 with improved glycemic control.

## SEC filing metadata
- accession: 0001193125-24-083352
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000119312524083352/0001193125-24-083352-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000119312524083352/d765540d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-083352
- JSON: https://secwatch.observer/filing/0001193125-24-083352.json
- Plain text: https://secwatch.observer/filing/0001193125-24-083352.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.